

THC Form 7

MONTHLY PROGRESS REPORT

February 2020

Name of CSE Issuer **THC BioMed Intl Ltd.**
Trading Symbol: **THC**
Number of Outstanding Listed Securities **159,543,056 common shares and 58,028,634 reserved for Issuance**
Date: **March 4, 2020**

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On February 6, 2020 the Issuer announced its intention to commence a normal course issuer bid ("NCIB") to purchase, from time to time over the following 12 months, an aggregate of 7,977,152 of its own common shares (the "Common Shares"), representing 5% of the issued and outstanding common shares as of February 6, 2020.

The Issuer may, if considered advisable, purchase the Common Shares through the facilities of the Canadian Securities Exchange ("CSE") and/or alternative trading systems.

Purchases commenced through the CSE on February 13, 2020. A total of 657,000 shares were purchased during the month of February for a total cost of \$92,890. The Issuer has appointed PI Financial Corp. to coordinate and facilitate its NCIB purchases.

The Issuer also announced that it continues to develop the proposed products THC Kiss beverage and Pure Cannabis Sticks. The THC Kiss beverage is currently undergoing stability testing, as required by regulations, and the production room for the Pure Cannabis Sticks was awaiting Health Canada approval. The Issuer intends to release these products within the next three to six months but cannot provide any assurances that this will happen.

On February 14, 2020 the Issuer announced that its *Cannabis Act* licence had been renewed by Health Canada for a further three years, until February 14, 2023.

On February 25, 2020 the Issuer announced that its Annual General and Special Meeting of shareholders (the "Meeting") was held in Vancouver, British Columbia on February 25, 2020. The Issuer reported that all matters submitted to shareholders

for approval as set out in the Issuer's Notice of Meeting and Information Circular, filed on January 20, 2020 and available on www.sedar.com, were approved.

The Issuer continued sales to medical patients through its website and to retail customers in Saskatchewan, Ontario and B.C.

2. Provide a general overview and discussion of the activities of management.

Management continues to work on the conduct of the company's business plan, growth and harvest of product, new product testing and expansion plans.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

The Issuer purchased a total of 657,000 Common Shares during the month of February for a total cost of \$92,890 as part of its NCIB. Purchases commenced

through the CSE on February 13, 2020. The Issuer has appointed PI Financial Corp. to coordinate and facilitate its NCIB purchases.

The consideration paid was determined by the market price and in accordance with the regulations applicable to NCIBs. The shares are to be returned to the Issuer's treasury for cancellation.

8. Describe the acquisition of new customers or loss of customers.

The Issuer has continued to register new patients.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

On February 14, 2020, the Issuer announced that its *Cannabis Act* license was renewed by Health Canada for a further three years, until February 14, 2023.

10. Report on any employee hiring's, terminations or lay-offs with details of anticipated length of lay-offs.

None, except in the ordinary course of business.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On February 28, 2020 the Issuer received, through its subsidiary THC Biomed Ltd., a \$1,000,000 mortgage from an arms-length lender on seven strata lots at its Acland Rd. location in Kelowna, B.C.

14. Provide details of any securities issued and options or warrants granted.

None.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

None.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer's business involves certain risks and uncertainties that are inherent to the Issuer's industry. For disclosure on risks related to an investment in the Issuer, please refer to the Issuer's most recent Management's Discussion and Analysis under the titles "Financial Instruments and Risk Management" and "Other Risks and Uncertainties", which is available on SEDAR at www.sedar.com.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to CSE that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CSE Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **March 4, 2020.**

John Miller

Name of Director or Senior Officer

"John Miller"

Signature

President and CEO

Official Capacity

Issuer Details		
Name of Issuer: THC BioMed Intl Ltd.	For Month End February	Date of Report: YYYYMMDD 2020/03/04
Issuer Address: P.O. Box 20033 Towne Centre		
City/Province/Postal Code: Kelowna, BC V1Y 9H2	Issuer Fax No.: N/A	Issuer Telephone No. (250) 870-2512
Contact Name: John Miller	Contact Position: President & CEO	Contact Telephone No. (250) 870-2512
Contact Email Address: info@thcbiomed.com	Web Site Address: www.thcbiomed.com	